Lord Abbett & CO. LLC Buys 23,451 Shares of CeriBell, Inc. $CBLL

Key Points

• Lord Abbett & CO. LLC increased its holdings in CeriBell, Inc. by 7.9%, now owning approximately 319,501 shares worth about $6.14 million as of its latest SEC filing.
• Insider transactions include Director Rebecca B. Robertson selling 11,188 shares and CEO Xingjuan Chao selling 25,000 shares, indicating a decrease of 52.70% and 3.12% in their respective positions.
• CeriBell's stock has a current price of $12.31 with a market cap of $451.28 million, while analysts have rated it with a consensus "Buy" and a target price of $32.14.

Lord Abbett & CO. LLC boosted its position in CeriBell, Inc. (NASDAQ:CBLL - Free Report) by 7.9% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 319,501 shares of the company's stock after purchasing an additional 23,451 shares during the period. Lord Abbett & CO. LLC owned about 0.89% of CeriBell worth $6,138,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Legal & General Group Plc purchased a new position in shares of CeriBell during the 4th quarter valued at about $32,000. Summit Investment Advisors Inc. bought a new stake in CeriBell during the 4th quarter valued at approximately $33,000. KLP Kapitalforvaltning AS bought a new stake in CeriBell during the 1st quarter valued at approximately $36,000. Tower Research Capital LLC TRC bought a new stake in CeriBell in the 4th quarter worth approximately $37,000. Finally, BNP Paribas Financial Markets bought a new stake in CeriBell in the 4th quarter worth approximately $43,000.

Insider Buying and Selling at CeriBell

In other CeriBell news, CEO Xingjuan Chao sold 25,000 shares of the company's stock in a transaction on Monday, July 7th. The stock was sold at an average price of $17.70, for a total value of $442,500.00. Following the completion of the sale, the chief executive officer directly owned 776,022 shares in the company, valued at approximately $13,735,589.40. This represents a 3.12% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Rebecca B. Robertson sold 11,188 shares of the company's stock in a transaction on Wednesday, June 18th. The stock was sold at an average price of $17.85, for a total value of $199,705.80. Following the completion of the sale, the director owned 10,042 shares of the company's stock, valued at $179,249.70. This represents a 52.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 88,633 shares of company stock valued at $1,541,261 over the last quarter. Company insiders own 20.10% of the company's stock.

Wall Street Analyst Weigh In

Separately, BTIG Research started coverage on CeriBell in a report on Tuesday, June 24th. They issued a "buy" rating and a $30.00 target price for the company. Eight investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, CeriBell currently has an average rating of "Buy" and a consensus price target of $32.14.

CeriBell Trading Down 1.8%

CBLL traded down $0.21 during trading hours on Wednesday, reaching $11.58. 220,089 shares of the company's stock traded hands, compared to its average volume of 290,935. The firm has a 50-day moving average price of $15.93 and a 200 day moving average price of $17.96. CeriBell, Inc. has a 52-week low of $10.01 and a 52-week high of $32.75. The company has a quick ratio of 12.91, a current ratio of 13.31 and a debt-to-equity ratio of 0.11. The firm has a market capitalization of $424.52 million and a PE ratio of -3.87.

CeriBell (NASDAQ:CBLL - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.40) by $0.02. CeriBell had a negative return on equity of 48.42% and a negative net margin of 63.83%.The company had revenue of $21.20 million during the quarter, compared to analysts' expectations of $20.52 million. CeriBell has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that CeriBell, Inc. will post -2.46 EPS for the current fiscal year.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.